THROUGH THE MPP ORGANIZATION, STELLA GETS THE APPROVAL TO PRODUCE PFIZER’S ANTI-COVID-19 PILL

On February 21, 2022, Stellapharm officially signed a contract with MPP (Medicines Patent Pool), a UNITED NATIONS-backed public health organization to become the only manufacturer in Vietnam allowed to produce a generic version of Pfizer’s oral COVID-19 treatment, nirmatrelvir, which will be co-packaged with ritonavir, under the voluntary licensing agreement between Pfizer and the MPP.

You May like

18 Feb 2022

Drug administration grants licences for first three made-in-Việt Nam Molnupiravir products

HÀ NỘI — The Drug Administration of Việt Nam under the Ministry of Health has issued the list of three COVID-19 treatment drugs produced in Việt Nam that contain the antiviral ingredient Molnupiravir, which have been granted certificates of registration for conditional use. The three products – Molravir 400mg produced by Boston Việt Nam Pharma (based in

21 Jan 2022

27 generic manufacturers sign agreements with MPP to produce low-cost versions of COVID-19 antiviral medication molnupiravir for supply in 105 low- and-middle-income countries

20 January 2022 Geneva – The Medicines Patent Pool (MPP) announced today that it has signed agreements with 27 generic manufacturing companies for the manufacturing of the oral COVID-19 antiviral medication molnupiravir and supply in 105 low- and-middle-income countries (LMICs). The sublicence agreements are the result of the voluntary licensing agreement signed by MPP and